Progress and Trend of CAR-T and PD-1 Blockade in the Treatment of Acute Myeloid Leukemia--Review.
10.19746/j.cnki.issn.1009-2137.2020.03.059
- Author:
Ji-Shi WANG
1
Author Information
1. Department of Hematology, The Affiliated Hospital of Guizhou Medical University, Guiyang 550001, Guizhou Province, China,E-mail：wangjishi9646@163.com.
- Publication Type:Journal Article
- MeSH:
Hematopoietic Stem Cell Transplantation;
Humans;
Immunotherapy, Adoptive;
Leukemia, Myeloid, Acute;
Programmed Cell Death 1 Receptor;
Receptors, Chimeric Antigen
- From:
Journal of Experimental Hematology
2020;28(3):1069-1074
- CountryChina
- Language:Chinese
-
Abstract:
Abstract Acute myeloid leukemia (AML) is a malignant clonal proliferative hematological tumor that originates from hematopoietic stem progenitor cells. Traditional chemotherapy can achieve complete remission in most patients, but so far, only allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only way to cure AML. Recurrence, drug resistance, and transplant-related deaths remain a key issue for AML treatment. Therefore, finding new treatments to improve the prognosis of patients with AML is urgently needed. In recent years, the emergence of new immunotherapy has revolutionized the concept of cancer treatment in the past few decades. Cellular immunotherapy represented by chimeric-antigen receptor T cell (CAR-T) and immunological detection point inhibitor represented by PD-1 blockade have achieved remarkable effects in hematological malignancies. This article mainly reviews the recent research progress of CAR-T and PD-1 blockade in the clinical treatment of AML.
